Mechanisms of inhibition of HIV replication by non-nucleoside reverse transcriptase inhibitors
about
Inhibitor-Based Therapeutics for Treatment of Viral HepatitisInhibitors of foot and mouth disease virus targeting a novel pocket of the RNA-dependent RNA polymeraseHIV-1 polymerase inhibition by nucleoside analogs: cellular- and kinetic parameters of efficacy, susceptibility and resistance selectionThe root extract of the medicinal plant Pelargonium sidoides is a potent HIV-1 attachment inhibitorHIV-1 drug resistance and resistance testing.Biophysical Insights into the Inhibitory Mechanism of Non-Nucleoside HIV-1 Reverse Transcriptase Inhibitors.Revealing the dimer dissociation and existence of a folded monomer of the mature HIV-2 proteaseA novel molecular mechanism of dual resistance to nucleoside and nonnucleoside reverse transcriptase inhibitors.N348I in reverse transcriptase provides a genetic pathway for HIV-1 to select thymidine analogue mutations and mutations antagonistic to thymidine analogue mutationsThe Role of Nucleotide Excision by Reverse Transcriptase in HIV Drug Resistance.N348I in HIV-1 reverse transcriptase can counteract the nevirapine-mediated bias toward RNase H cleavage during plus-strand initiation.4'-Ethynyl-2-fluoro-2'-deoxyadenosine (EFdA) inhibits HIV-1 reverse transcriptase with multiple mechanismsReduced fitness in cell culture of HIV-1 with nonnucleoside reverse transcriptase inhibitor-resistant mutations correlates with relative levels of reverse transcriptase content and RNase H activity in virions.Subtype-associated differences in HIV-1 reverse transcription affect the viral replication.HIV-1 antiretroviral resistance: scientific principles and clinical applicationsAllosteric suppression of HIV-1 reverse transcriptase structural dynamics upon inhibitor bindingA cell-based strategy to assess intrinsic inhibition efficiencies of HIV-1 reverse transcriptase inhibitors.A review of the virological efficacy of the 4 World Health Organization-recommended tenofovir-containing regimens for initial HIV therapy.Ligand similarity guided receptor selection enhances docking accuracy and recall for non-nucleoside HIV reverse transcriptase inhibitors.Interaction of HIV-1 reverse transcriptase ribonuclease H with an acylhydrazone inhibitor.NMR characterization of HIV-1 reverse transcriptase binding to various non-nucleoside reverse transcriptase inhibitors with different activities.Structural basis of the allosteric inhibitor interaction on the HIV-1 reverse transcriptase RNase H domain.Efavirenz enhances HIV-1 gag processing at the plasma membrane through Gag-Pol dimerizationFormation of a quaternary complex of HIV-1 reverse transcriptase with a nucleotide-competing inhibitor and its ATP enhancer.Mutations M184V and Y115F in HIV-1 reverse transcriptase discriminate against "nucleotide-competing reverse transcriptase inhibitors".Hypersusceptibility mechanism of Tenofovir-resistant HIV to EFdA.Role of the K101E substitution in HIV-1 reverse transcriptase in resistance to rilpivirine and other nonnucleoside reverse transcriptase inhibitorsEfavirenz stimulates HIV-1 reverse transcriptase RNase H activity by a mechanism involving increased substrate binding and secondary cleavage activity.Mechanism of inhibition of HIV-1 reverse transcriptase by 4'-Ethynyl-2-fluoro-2'-deoxyadenosine triphosphate, a translocation-defective reverse transcriptase inhibitor.The connection domain mutation N348I in HIV-1 reverse transcriptase enhances resistance to etravirine and rilpivirine but restricts the emergence of the E138K resistance mutation by diminishing viral replication capacity.Novel HIV-1 non-nucleoside reverse transcriptase inhibitors: a patent review (2005 - 2010).Specific microbicides in the prevention of HIV infection.In search of a treatment for HIV--current therapies and the role of non-nucleoside reverse transcriptase inhibitors (NNRTIs).HIV-associated cellular senescence: A contributor to accelerated aging.The triple combination of tenofovir, emtricitabine and efavirenz shows synergistic anti-HIV-1 activity in vitro: a mechanism of action study.Can Antiretroviral Drugs Be Used to Treat Porcine Endogenous Retrovirus (PERV) Infection after Xenotransplantation?Guanine α-carboxy nucleoside phosphonate (G-α-CNP) shows a different inhibitory kinetic profile against the DNA polymerases of human immunodeficiency virus (HIV) and herpes viruses.Substituted indoles as HIV-1 non-nucleoside reverse transcriptase inhibitors: a patent evaluation (WO2015044928).Double Variational Binding--(SMILES) Conformational Analysis by Docking Mechanisms for Anti-HIV Pyrimidine Ligands.Connection domain mutations N348I and A360V in HIV-1 reverse transcriptase enhance resistance to 3'-azido-3'-deoxythymidine through both RNase H-dependent and -independent mechanisms.
P2860
Q28073697-58603DC6-DCD7-4AA6-B52A-17F05F8C4C35Q28476610-229ACBDB-E3C3-49DF-BF83-EBAB465A13C1Q28478993-FA38060C-95D2-4FC5-B67A-B9E5CA3EA209Q28539308-2A2E641B-B806-44CF-A08C-CBD14FB1E4EDQ30245693-7F9C2055-672E-4162-AA7E-BE51EC1C4E64Q33649797-029D8898-99AC-4C31-B281-3EB8ABB39191Q33650307-1A66835F-19A2-4727-9EE3-8F5041E480BCQ33826904-14C37586-E767-4377-9DFC-980BBEFD7185Q33869951-D4628BC0-519E-4F3E-A18B-4EA1F8EE957AQ33889635-3A1D7E68-3538-4F72-AB77-3AAAB1FAA6C8Q34094395-632CD440-8E61-479B-ABA7-D74C267B46C1Q34107343-8D884331-2894-4BB5-A7A5-155AC440DEA4Q34120147-37AAB847-2680-48B9-83AE-3C698EA9DAF7Q34243467-3769FE16-2711-4B3C-8CCF-82E52955DBB8Q34280466-033B72DE-7D2C-4DF0-A081-DAD4EDE5BF42Q34439424-CC144572-A25F-448D-8CED-7FB7C8E8569FQ35105821-60791D59-5B9E-4E9F-A5F5-EE42B5C8AA57Q35771321-9A7AD38C-7D19-4BC0-93E3-0D326FBA1AD0Q35801074-46789A64-D358-4811-9A3D-7EF459ED79D1Q35874082-732AE85C-9D6A-4C7E-BE4E-D586D2196AC6Q36221687-3E5650F4-5B88-4C1A-9A22-696E9FA81D5AQ36300994-9E3C5F7E-4FD1-4653-A394-DF8480879E4AQ36667876-F6E24999-4E49-4158-A535-021F6680446DQ36928993-6B950E7B-B5C8-4C71-9ED9-C1C93AA38FDCQ36949351-68F792B6-33E9-4F48-9948-46DDBB3AC355Q36964321-04984747-C832-4C3A-BFDE-3D18157F8F82Q37263541-BA988AC1-3C89-4628-88F7-152D601EB8FAQ37350895-9CB54238-87E8-4909-A413-7E06DE2580FFQ37467660-F07B5445-4D7B-413C-ABAB-4E2383BF531CQ37547275-31BB0D38-A995-477D-9462-475BD99B2240Q37860335-BDB443A3-E07D-4BC6-BF80-0648C5117E3EQ37932048-0612853E-8A1B-4AD2-90E1-93C5779B3879Q38012389-204234AF-CC4D-4B90-81BF-A5EAF7A0511FQ39054700-FE633259-49B1-4861-9243-227F6CD33984Q39852169-01E392D6-8039-45AF-99E5-58B521501813Q40090982-391651E3-0DD0-473E-93CD-15F10E06B604Q40251943-F70BC486-7B04-4BD4-9F05-184CF5E632F6Q40841438-294ABB8B-6C21-4C9A-9615-C33CC770E966Q41040182-47652DF8-BA03-4B5D-BFC5-67F398974DF3Q41262484-DC5E653F-AE7A-403B-832F-A12B82C61D0E
P2860
Mechanisms of inhibition of HIV replication by non-nucleoside reverse transcriptase inhibitors
description
2008 nî lūn-bûn
@nan
2008 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Mechanisms of inhibition of HI ...... verse transcriptase inhibitors
@ast
Mechanisms of inhibition of HI ...... verse transcriptase inhibitors
@en
Mechanisms of inhibition of HI ...... verse transcriptase inhibitors
@nl
type
label
Mechanisms of inhibition of HI ...... verse transcriptase inhibitors
@ast
Mechanisms of inhibition of HI ...... verse transcriptase inhibitors
@en
Mechanisms of inhibition of HI ...... verse transcriptase inhibitors
@nl
prefLabel
Mechanisms of inhibition of HI ...... verse transcriptase inhibitors
@ast
Mechanisms of inhibition of HI ...... verse transcriptase inhibitors
@en
Mechanisms of inhibition of HI ...... verse transcriptase inhibitors
@nl
P2860
P3181
P1433
P1476
Mechanisms of inhibition of HI ...... verse transcriptase inhibitors
@en
P2093
Nicolas Sluis-Cremer
P2860
P304
P3181
P356
10.1016/J.VIRUSRES.2008.01.002
P407
P577
2008-06-01T00:00:00Z